#ES­MO22: De­ci­phera pins its come­back hopes on im­proved TGCT da­ta

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther­a­py for gas­troin­testi­nal stro­mal tu­mors (GIST) but then failed in an at­tempt to move up­stream in the treat­ment sce­nario — es­sen­tial­ly rel­e­gat­ing it to mi­nor sales rev­enue in­stead of the block­buster po­ten­tial some an­a­lysts had paint­ed.

That knock­down, which sent its stock in­to a tail­spin the biotech has not re­cov­ered from, forced the De­ci­phera team to un­der­go a thor­ough re­assess­ment of the pipeline, and a move to cull its work and fo­cus on the clin­i­cal pro­gram for vim­sel­tinib, a CSF1R in­hibitor be­ing stud­ied as a ther­a­py for tenosyn­ovial gi­ant cell tu­mor — or TGCT.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER